CHESS-SAVE Score to Stratify Decompensation Risk in Compensated Advanced Chronic Liver Disease (CHESS2102)

CHESS-SAVE Score to Stratify Decompensation Risk in Compensated Advanced Chronic Liver Disease: an International Multicenter Study (CHESS2102)

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04975477

Enrollment

1000

Registered

2021-07-23

Start date

2021-07-16

Completion date

2021-08-16

Last updated

2021-07-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Compensated Advanced Chronic Liver Disease

Keywords

liver stiffness, platelets, albumin, varices, compensated cirrhosis

Brief summary

Compensated advanced chronic liver disease (cACLD) was associated with a high rate of variceal bleeding, ascites, and hepatic encephalopathy due to portal hypertension. In these patients, esophagogastroduodenoscopy and hepatic venous pressure gradient were recommended methods to evaluate portal hypertension. However, non-invasive predictors of outcomes to stratify care remains needed. Although the updated EASL guideline has recommended that patients with liver stiffness \>20kPa or platelets \<150\*10\^9/L had the high risk of decompensation, the criteria remains to be validated. This international multicenter study aims to develop a novel CHESS-SAVE score to further predict the risk of liver decompensation in cACLD patients.

Detailed description

Compensated advanced chronic liver disease (cACLD) was associated with a high rate of variceal bleeding, ascites, and hepatic encephalopathy due to portal hypertension. In these patients, esophagogastroduodenoscopy and hepatic venous pressure gradient were recommended methods to evaluate portal hypertension. However, non-invasive predictors of outcomes to stratify care remains needed. Although the updated EASL guideline has recommended that patients with liver stiffness \>20kPa or platelets \<150\*10\^9/L had the high risk of decompensation, the criteria remains to be validated. This international multicenter study initialed and enrolled by Chinese Portal Hypertension Alliance (CHESS) aims to develop a novel CHESS-SAVE score to further predict the risk of liver decompensation in cACLD patients.

Interventions

PROCEDUREEsophagogasrtoduodendoscopy and liver stiffness

Time frame between elastography measurement and esophagogastroduodendoscopy is within 6 months.

PROCEDUREhepatic venous pressure gradient

A method was used to evaluate portal pressure.

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

Training and validation cohort Inclusion Criteria: * age more than 18 years; * fulfilled diagnosis of cACLD based on radiological, histological features of liver cirrhosis

Exclusion criteria

* prior liver decompensation; * hepatocellular carcinoma; * prior liver transplantation; * portal vein thrombosis; * antiplatelet or anticoagulation; * without screening EGD within six months of TE; * incomplete follow-up data. HVPG cohort Inclusion Criteria: * age more than 18 years; * fulfilled diagnosis of cACLD based on radiological, histological features of liver cirrhosis

Design outcomes

Primary

Measure	Time frame	Description
Accuracy of the CHESS-SAVE score for predicting liver decompensation	3 years	To assess the accuracy of the CHESS-SAVE score to predict liver decompensation in patients with compensated advanced chronic liver disease

Countries

China, Egypt, India, Japan, South Korea

Contacts

Primary ContactXiaolong Qi, MD

qixiaolong@vip.163.com+8618588602600

Backup ContactChuan Liu, MD

845424585@qq.com

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026